Armata Pharmaceuticals Return on Equity

Armata Pharmaceuticals (ARMP) currently reports a ROE of 83.13%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Armata Pharmaceuticals's ROE history and peer comparisons.

Armata Pharmaceuticals's ROE of 83.13% is higher than the Healthcare sector average of 22.01%. That is roughly 277.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Armata Pharmaceuticals's current 83.13% should be judged against Healthcare norms (sector average: 22.01%) and against ARMP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 83.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Armata Pharmaceuticals, and consider following ARMP for alerts when major investors trade the stock.

Armata Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 83.13% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARMP with unrelated industries.